Madhu Kumar
Stock Analyst at Goldman Sachs
(2.87)
# 1,653
Out of 4,862 analysts
153
Total ratings
55.45%
Success rate
18.84%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $110.30 | +53.23% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $6.78 | -11.50% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.12 | +7.79% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $13.41 | +26.77% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.62 | +146.91% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $142.19 | +9.01% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $33.20 | +59.64% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.96 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $16.22 | +350.06% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $19.28 | +631.33% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $10.67 | +218.65% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.31 | +159.74% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $12.64 | +10.76% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.41 | +101.83% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $15.43 | -67.60% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.18 | +266.97% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $7.57 | +1,075.69% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.43 | +1,289.85% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.37 | +2,639.73% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $8.35 | +917.96% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.37 | +2,753.38% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $15.99 | +256.47% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.58 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.92 | +46,775.00% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.22 | +283.14% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.20 | +8,233.33% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $33.29 | +5.14% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.42 | +14,111.27% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $8.86 | +351.47% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $17.15 | +2,838.78% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $304.67 | -24.51% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $8.08 | +642.57% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.80 | +4,900.00% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $37.37 | -42.47% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $41.28 | -43.07% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $110.30
Upside: +53.23%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.78
Upside: -11.50%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.12
Upside: +7.79%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $13.41
Upside: +26.77%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.62
Upside: +146.91%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $142.19
Upside: +9.01%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $33.20
Upside: +59.64%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.96
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $16.22
Upside: +350.06%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $19.28
Upside: +631.33%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $10.67
Upside: +218.65%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.31
Upside: +159.74%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $12.64
Upside: +10.76%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.41
Upside: +101.83%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $15.43
Upside: -67.60%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.18
Upside: +266.97%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $7.57
Upside: +1,075.69%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.43
Upside: +1,289.85%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.37
Upside: +2,639.73%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $8.35
Upside: +917.96%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.37
Upside: +2,753.38%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $15.99
Upside: +256.47%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.58
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.92
Upside: +46,775.00%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.22
Upside: +283.14%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.20
Upside: +8,233.33%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $33.29
Upside: +5.14%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.42
Upside: +14,111.27%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $8.86
Upside: +351.47%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $17.15
Upside: +2,838.78%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $304.67
Upside: -24.51%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $8.08
Upside: +642.57%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $0.80
Upside: +4,900.00%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $37.37
Upside: -42.47%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $41.28
Upside: -43.07%